Confidential Independent Evaluation

Substance use evaluation for private and fiduciary contexts — Minnesota 

Some clinical evaluations occur in contexts where the conditions of the evaluation — confidentiality, structural independence, and the deliberate absence of insurance and third-party documentation — are themselves material to the integrity of the work. The decisions the evaluation will inform may involve trust administration and fiduciary distribution determinations, family enterprise and succession considerations, professional and reputational standing, anticipated regulatory or employer disclosure events, or private clinical questions for which a structured independent reference is sought. In these contexts, the practice's operational structure — not only its methodology — is what allows the evaluation to function as the document the decision-making context requires.

Arlucent Assessments provides confidential independent substance use evaluation for individuals and for fiduciary, advisory, and counsel-mediated engagements where these conditions apply. Evaluations are conducted by secure telehealth and follow the American Society of Addiction Medicine (ASAM) Criteria, Minnesota DHS 245G regulatory standards, and DSM-5/ICD-10 diagnostic conventions. The practice is assessment-only — no treatment, no therapy, no insurance, no claims data generated, and no continuing clinical relationship. The evaluating clinician's role concludes with delivery of the written clinical report.

Confidential evaluations commissioned through Arlucent Assessments™ operate at the same architectural depth as the practice's other service offerings, with the additional structural conditions (private-pay only, no insurance involvement, no claims data generated, discreet operational posture) that the confidential context requires. The clinical evaluation operates the Screening, Tracking, and Analysis layers of the STABLE™ architecture; the structural conditions of the engagement are what allow the resulting documentation to function in fiduciary, governance, and pre-disclosure contexts. 

Four operational features distinguish the practice and define the scope within which it engages.

Engagements are private-pay only. The practice does not accept insurance, does not bill third-party payors, does not generate claims data, and does not submit utilization review documentation. No record of the engagement appears in insurance medical history, in claims databases queried by underwriters, or in payor-side data structures accessible through subpoena to insurers. The clinical record exists within the practice's documentation system and is governed by standard professional confidentiality conventions; transmission of any portion of the record to a third party occurs only with the individual's written authorization.

The practice provides no treatment, no therapy, no aftercare, no recovery coaching, no referrals to affiliated programs, and no ongoing clinical relationship. There is no organizational benefit to producing any particular finding, recommending any particular level of care, or reaching any particular conclusion. The evaluating clinician has no financial or operational interest in the outcome of the evaluation beyond the production of an accurate clinical document. This structural condition is the basis on which the evaluation can function as an independent clinical reference rather than as documentation produced under structurally ambiguous conditions.

The practice does not maintain a public client list, does not publish case studies, does not reference specific engagements in any marketing materials, and does not solicit testimonials. Engagement records, scheduling, and correspondence are conducted under standard professional confidentiality conventions. The practice operates a single-evaluator model; there is no broader staff structure with incidental access to clinical records.

Evaluations are conducted entirely by secure telehealth across Minnesota. No in-person attendance at a clinical facility is required at any stage. The telehealth structure is the practice's primary delivery model; it was selected at founding for clinical and operational reasons and is not a pandemic-era accommodation.

Estate planning counsel, trust officers, family office staff, family enterprise advisors, and counsel in related practice areas occasionally encounter client situations in which an independent substance use evaluation is appropriate. The practice is structured to serve these engagements without compromising the advisor's relationship with the client or the structural integrity of the documentation.

Modern trust instruments increasingly include conditional distribution provisions, trustee discretion language, and behavioral compliance triggers whose administration requires structured clinical assessment. A trustee confronting a distribution decision tied to documented sobriety, behavioral stability, or related conditions requires evaluation documentation that supports the decision and that withstands subsequent beneficiary review. The practice provides such documentation under conditions that are structurally appropriate for fiduciary use: independent of treatment interests, independent of beneficiary or grantor preferences, and methodologically rigorous in a way that supports the trustee's administration record.

Estate planning attorneys drafting instruments that contemplate substance use considerations — conditional distributions, supplemental needs provisions, contingent beneficiary structures, or analogous provisions — occasionally have client questions that benefit from a structured clinical reference before instrument language is finalized. The practice does not draft or interpret legal instruments and does not produce documentation intended to substitute for legal analysis; the evaluation documents the clinical picture against which the instrument language will subsequently operate.

Where trust administration becomes disputed, where capacity questions arise in connection with substance use, or where beneficiary challenges raise clinical questions, independent evaluation may inform the evidentiary considerations available to counsel. The practice produces clinical documentation; it does not provide expert witness testimony, deposition appearance, or trial work. Where litigation may follow the evaluation, this scope limitation should be considered at the engagement stage.

Individuals anticipating a regulatory, professional, or reputational disclosure event sometimes pursue independent evaluation to inform their deliberation before formal proceedings or public events. Counsel and advisors managing such situations may find the practice useful as a structurally appropriate evaluator. The pre-disclosure evaluation is held by the individual and is not transmitted absent explicit authorization.

Family enterprise structures and family office governance occasionally surface substance use concerns regarding principals, heirs, or family members in positions affecting enterprise or asset decisions. The practice can serve as an independent evaluator in these contexts, working alongside family office leadership, family counsel, or family enterprise consultants as the engagement structure requires.

 The practice operates a three-tier assessment architecture calibrated to case complexity: the Arlucent Standard ASAM Assessment (ASAA), the Arlucent Clinical Assessment (ACA), and the Arlucent Comprehensive Systems Assessment™ (ACSA). Confidential evaluations are typically conducted at the ACA or ACSA tier; the diagnostic and analytic complexity of the contexts described above generally exceeds the scope the ASAA is designed to address. Tier selection is determined at intake based on case posture, prior assessment history, the clinical question presented, and the intended use of the report.

The ACA and ACSA tiers incorporate The Arlucent Seventh Dimension™, a proprietary analytic framework for behavioral coherence and value-behavior alignment. The framework is particularly relevant in fiduciary, governance, and pre-disclosure contexts, where the operative question often concerns the alignment between an individual's stated commitments and their documented behavior over time — a question that ASAM dimensional analysis addresses partially but that benefits from the structured supplementary analytic layer the framework provides.

Reports are organized to distinguish documented evidence, structured clinical analysis, and evaluator conclusions. Diagnostic conclusions are documented with severity specifiers and evidentiary basis. Level-of-care opinions, where included, are framed as clinical opinion and explicitly distinguished from placement authorization or treatment mandate. The report does not adopt advocacy posture and does not produce conclusions about legal, fiduciary, or governance determinations that fall outside the scope of clinical assessment; those determinations are reserved to the operative authority — the trustee, the counsel, the family office leadership, the individual, or the regulating body, as the case may be.

Detailed methodology and tier specifications are documented on the Methodology page. Further information on the behavioral coherence framework is available on the Arlucent Seventh Dimension™ page.

Engagements may be initiated directly by the individual or through counsel or advisors acting with the individual's authorization. The intake process is brief and confidential. Following intake review, eligible engagements are confirmed in writing, with scope, tier, documentation requirements, scheduling, and fees identified before scheduling. The structured evaluation is conducted by secure telehealth; the written report is prepared and delivered to the individual or to the authorized recipient identified at engagement.

Fees are private-pay and are confirmed in writing at the engagement stage; the practice does not publish fee schedules and does not discuss fees outside the engagement-specific intake context. Engagements requiring expedited scheduling, broader documentation scope, or multi-stakeholder coordination are accommodated where capacity permits; such accommodations are confirmed at intake.

Evaluations are conducted by Rafael Lewis, M.A., LADC — founder of Arlucent Assessments, Licensed Alcohol and Drug Counselor in Minnesota, doctoral student in counseling psychology at Saint Mary's University of Minnesota, and developer of The Arlucent Seventh Dimension™ framework. Mr. Lewis's clinical and administrative experience includes leadership roles in licensed substance use treatment settings, providing direct working knowledge of the methodologies, regulatory standards, and structural considerations relevant to high-stakes independent evaluation work.

Additional information on credentialing, professional accountability, and scope of practice is available on the About page.

Engagement begins with intake review. Individuals may complete the intake questionnaire directly; counsel and advisors may initiate the inquiry on behalf of a client with the client's authorization. Intake review is confidential and is used to confirm scope, appropriate assessment tier, and engagement structure. All subsequent details — scheduling, documentation, fees — are confirmed in writing following intake review.

Scheduled engagements are confirmed only after payment is received. Inquiries from counsel and advisors are welcome.